TH (N)



CERTIFICATE OF MAILING 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

August 26, 2005

Date

Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Sophia Ran

Serial No.: 09/351,862

Filed: July 12, 1999

For: CANCER TREATMENT KITS USING

ANTIBODIES TO

AMINOPHOSPHOLIPIDS

Group Art Unit: 1617

Examiner: Sharareh, S.

Atty. Dkt. No.: 4001.002282

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that the present Supplemental Information Disclosure Statement be entered and the document listed on the enclosed Form PTO-1449 be considered by the Examiner and made of record in the present case. According to 37 C.F.R. § 1.98(a)(2)(ii), copies of published U.S. patent applications are no longer required.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A non-Final Official Action reflecting examination on the merits has been received in the

present application. However, this Supplemental Information Disclosure Statement is being filed

prior to the mailing of a Final Official Action, notice of allowance or an Action that closes

prosecution, and is timely filed in accordance with 37 C.F.R. § 1.97(c) without a fee in light of

the following information.

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the document listed

in the accompanying Form PTO-1449 was not cited in a communication from a foreign patent

office in a foreign counterpart to the present application. The listed document is a U.S. patent

application published on May 26, 2005, and could not have been submitted before publication.

The present statement is being filed within three months of the date of publication, and is thus

timely.

No fees are due in connection with the filing of this Supplemental Information Disclosure

Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for

any reason, the Examiner should contact the undersigned representative to discuss deduction

from Peregrine Pharmaceuticals, Inc. Deposit Account No. 50-3493/4001.002282.

Respectfully submitted,

PEREGRINE PHARMACEUTICALS, INC.

Customer No. 000052101

Shelley P.M. Fussey, Ph.D.

Reg. No. 39,458 Agent for Applicants

5353 W. Alabama, Suite 306 Houston, Texas, 77056 (832) 886-5834

Date: August 26, 2005

Form PTO-1449 (modified) List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT					Temp. Atty. Docket No. 4001.002282			Serial No. 09/351,862		
					Applicant Thorpe et al.					
	(Use s	several sheets if necessary	Filing Date: July 12, 1999			Group: 167				
U.S. Patent Documents See Page 1			•	Foreign Patent Documen See Page		Other Art See Page				
			U.S. Pate	nt Do	cuments					
Exam. Init.	Ref. Des.	Document Number	Date		Name	Clas	ss Sub Class	Filing Date of App.		
	A35	2005.0113297 A1	May 26, 20	François et al.		514	1 12			
		Fo	reign Pa	tent D	ocument	<u> </u>				
Exam. Init.	Ref. Des.	Document Number	Date		Country	Clas	s Sub Class	Translation Yes/No		
(Other .	Art (Including	g Author,	Title,	Date Perf	inen	t Pages,	Etc.)		
Exam. Init.	m. Ref. Citation									
Exami	NER:			DA	TE CONSIDEI	RED:				

Information Disclosure Statement — PTO-1449 (Modified)